Abstract:Adoptive cell transfer (ACT) with autologous tumor-reactive T-cells has recently shown great promise in the treatment of leukemias in clinical trials. However, effective control of solid tumors, in particular resistant, metastatic, or recurrent cancers, remain challenging. One of the major limitations is the rapid decline of T-cell function in the immunosuppressive tumor microenvironment. In order to maintain high numbers of viable antigen-specific cytotoxic T-cells in tumors, co-administration of supporting immunostimulant agents such as cytokines together with transferred cells is often employed. However, the high systemic doses of such agents needed to enhance T-cell functionality inside solid tumors can also result in serious side effects. Here, we developed a cell-responsive nanogel (NG) based on a novel carrier-free delivery strategy to effectively and specifically support adoptively transferred T-cells with recombinant cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). IL-2-Fc or an IL-15 superagonist (IL-15Sa) were chemically crosslinked with a disulfide linker to form these protein NGs, which were subsequently bound to and stably anchored on the plasma membrane of adoptively transferred T-cells ex vivo. These NGs had exceptionally high loading of cytokines (~70 wt%) and released native cytokine proteins in physiological condition in a sustained manner through breakdown of a degradable disulfide linker in response to the reduction activity at the plasma membrane surface of activated T-cells, and thus enabled continuous pseudo-autocrine stimulation of transferred CD8+ T-cells. In a mouse model of subcutaneous B16F10 melanoma tumors, adoptively transferred mouse pmel-1 CD8+ T-cells with optimized IL-15Sa-NGs showed markedly enhanced expansion and persistence in tumors and thus improved the anti-cancer efficacy. Quantification of transferred tumor-specific T-cells in tumors 7 days after transfer showed that surface-bound IL-15Sa-NGs resulted in ~16-fold more tumor-reactive T-cells compared to T-cells supported by an equivalent dose of soluble IL-15Sa administered systemically. Surface-bound IL-15Sa-NGs could be used to “backpack” T-cells with doses of cytokine that slowly released and maintained T-cell function over at least 2 weeks in vivo, while the same doses administered systemically as a bolus or repeated lower-dose injections were very toxic, eliciting systemic cytokine syndrome. These data demonstrate that T-cell surface-bound responsive cytokine-NGs provide autocrine support to the tumor-reactive T-cells to enhance efficacy of ACT therapy against solid tumors and safely administered potent adjuvant immunostimulants to donor T-cells. Citation Format: Li Tang, Yiran Zheng, Llian Mabardi, Darrell Irvine. T lymphocyte engineering with responsive cytokine nanogels for enhanced efficacy and safety of adoptive cell therapy for cancer. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B53.

Allogeneic LAK cells in adoptive immunotherapy of advanced cancers. A report on 38 cases

Treatment of Patients with Malignant Pleural Effusions Due to Advanced Lung Cancer by Transfer of Autologous LAK Cells Combined with Ril-2 or Ril-2 Alone.

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans

Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer

Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report

Abstract A044: Meta-analysis of adoptive natural killer cell transfer immunotherapy against solid cancers in human patients

Potential elimination of multi-drug resistant cancer cells by targeted non-engrafting intentionally mismatched activated donor lymphocytes.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Advancing Adoptive Cell Therapy: Optimized Expansion of Adaptive NK Cells for Solid Tumors

Phase Ia Clinical Trial Of Adoptively Transferring Peripheral Blood-Derived Cytotoxic T Lymphocytes Targeting Individual Neo-Antigens To Treat Patients With Advanced Solid Tumor.

Effection of autologous PHA-LAK cells adoptive immunotherapy on phenotypes and function of lymphocytes in patients with solid tumor

Clinical Observation of Adoptive Immunotherapy Using Autologous CD3AK Cells in Treatment of Advanced Malignant Tumor

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors

Allogeneic Hematopoietic Stem Cell Transplantation for 74 Patients with Refractory Acute Lymphoblastic Leukemia Following Sequential Intensified Conditioning Combined with Graft-Versus-leukemia Induction

Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique

Large-Scale Expansion of Leukemia Specific CTLs Using Lysates-Pulsed Dendritic Cell and Low-Dose IL-2 for Adoptive Immunotherapy

Allogenetic peripheral blood stem cell transplantation for patients with acute/chronic leukemia:clinical observation in 52 cases

Allogeneic V9V2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

Human Leukocyte Antigen-Haploidentical Donor-Derived Cytokine-Induced Killer Cells Are Safe and Prolong the Survival of Patients with Advanced Non-Small Cell Lung Cancer.

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

T Lymphocyte Engineering With Responsive Cytokine Nanogels For Enhanced Efficacy And Safety Of Adoptive Cell Therapy For Cancer